Nutra Pharma Corp
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin, an over-the-counter (OTC) pain reliever; Nyloxin Extra Strength, a non-narcotic and non-addictive treatment fo… Read more
Nutra Pharma Corp (NPHC) - Total Liabilities
Latest total liabilities as of September 2024: $15.38 Million USD
Based on the latest financial reports, Nutra Pharma Corp (NPHC) has total liabilities worth $15.38 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nutra Pharma Corp - Total Liabilities Trend (2001–2025)
This chart illustrates how Nutra Pharma Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nutra Pharma Corp Competitors by Total Liabilities
The table below lists competitors of Nutra Pharma Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gujarat Raffia Industries Limited
NSE:GUJRAFFIA
|
India | ₹79.77 Million |
|
ASM Automation Group Berhad
KLSE:0362
|
Malaysia | RM9.82 Million |
|
Haffner Energy SA
PA:ALHAF
|
France | €14.12 Million |
|
Compagnie Industrielle et Financière d'Entreprises SA
PA:INFE
|
France | €182.41 Million |
|
CPL Group Public Company Limited
BK:CPL
|
Thailand | ฿1.45 Billion |
|
INCREDIBLE INDUSTRIES LIMITED
NSE:INCREDIBLE
|
India | ₹437.98 Million |
|
Johan Holdings Bhd
KLSE:3441
|
Malaysia | RM196.43 Million |
|
NorthView Acquisition Corporation Warrant
PINK:NVACW
|
USA | $23.14 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Nutra Pharma Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 27.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nutra Pharma Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nutra Pharma Corp (2001–2025)
The table below shows the annual total liabilities of Nutra Pharma Corp from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $13.13 Million | -8.86% |
| 2023-12-31 | $14.41 Million | +9.72% |
| 2022-12-31 | $13.13 Million | -39.36% |
| 2021-12-31 | $21.66 Million | +256.33% |
| 2020-12-31 | $6.08 Million | -49.52% |
| 2019-12-31 | $12.04 Million | +98.11% |
| 2018-12-31 | $6.08 Million | +4.80% |
| 2017-12-31 | $5.80 Million | +23.63% |
| 2016-12-31 | $4.69 Million | +18.40% |
| 2015-12-31 | $3.96 Million | -0.50% |
| 2014-12-31 | $3.98 Million | -8.43% |
| 2013-12-31 | $4.35 Million | +12.11% |
| 2012-12-31 | $3.88 Million | -6.30% |
| 2011-12-31 | $4.14 Million | +26.21% |
| 2010-12-31 | $3.28 Million | +36.84% |
| 2009-12-31 | $2.40 Million | -10.00% |
| 2008-12-31 | $2.66 Million | +27.02% |
| 2007-12-31 | $2.10 Million | +6.52% |
| 2006-12-31 | $1.97 Million | +147.92% |
| 2005-12-31 | $794.07K | +45.19% |
| 2004-12-31 | $546.91K | -42.53% |
| 2003-12-31 | $951.73K | +10.10% |
| 2002-12-31 | $864.41K | -51.10% |
| 2001-12-31 | $1.77 Million | -- |